Extended Data Fig. 10: Expansion dynamics of TCR clones from baseline to on-therapy to time of resistance in 2 partial responders in the SBRT arm and 1 partial responder in the control arm who developed resistance to treatment.
Patients 680 and 690 were in the SBRT cohort, while patient 743 was in the control arm. All clones that significantly expanded from baseline to on therapy samples are visualized, stratified by location of on-therapy expansion (tumor vs blood, columns), then by expansion status at time of resistance relative to baseline abundances (no sustained increase vs sustained increase in tumor vs sustained increase in blood, rows). Most clones that expanded on treatment in SBRT patients showed no sustained expansion at time of acquired resistance (7% sustained intra-tumoral TCR expansion, 14% sustained blood TCR expansion). Similar patterns were noted for the patient in the control arm regarding intra-tumoral TCR clones, though notably more clones remained expanded in the blood compartment at time of resistance (3% sustained intra-tumoral TCR expansion, 63% sustained blood TCR expansion).
